A collaborative analysis of individual participant data from 19 prospective studies assesses circulating Vitamin D and prostate cancer risk

Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Previous prospective studies assessing the relationship between circulating concentrations of vitamin D and prostate cancer risk have shown inconclusive results, particularly for risk of aggressive disease. In this study, we examine the association between prediagnostic concentrations of 25-hydroxyvitamin D [25(OH)D] and 1,25-dihydroxyvitamin D [1,25(OH) 2 D] and the risk of prostate cancer overall and by tumor characteristics. Principal investigators of 19 prospective studies provided individual participant data on circulating 25(OH)D and 1,25(OH) 2 D for up to 13,462 men with incident prostate cancer and 20,261 control participants. ORs for prostate cancer by study-specific fifths of season-standardized vitamin D concentration were estimated using multivariable-adjusted conditional logistic regression. 25(OH)D concentration was positively associated with risk for total prostate cancer (mul-tivariable-adjusted OR comparing highest vs. lowest study-specific fifth was 1.22; 95% confidence interval, 1.13–1.31; P trend < 0.001). However, this association varied by disease aggressiveness (P heterogeneity ¼ 0.014); higher circulating 25(OH)D was associated with a higher risk of nonaggressive disease (OR per 80 percentile increase ¼ 1.24, 1.13–1.36) but not with aggressive disease (defined as stage 4, metastases, or prostate cancer death, 0.95, 0.78–1.15). 1,25(OH) 2 D concentration was not associated with risk for prostate cancer overall or by tumor characteristics. The absence of an association of vitamin D with aggressive disease does not support the hypothesis that vitamin D deficiency increases prostate cancer risk. Rather, the association of high circulating 25(OH)D concentration with a higher risk of nonaggressive prostate cancer may be influenced by detection bias. Significance: This international collaboration comprises the largest prospective study on blood vitamin D and prostate cancer risk and shows no association with aggressive disease but some evidence of a higher risk of nonaggressive disease.

Original languageEnglish
Pages (from-to)274-285
Number of pages12
JournalCancer Research
Volume79
Issue number1
DOIs
Publication statusPublished - 1 Jan 2019

Cite this

Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group. / A collaborative analysis of individual participant data from 19 prospective studies assesses circulating Vitamin D and prostate cancer risk. In: Cancer Research. 2019 ; Vol. 79, No. 1. pp. 274-285.
@article{84f83be313b64e8aa8f6470bf53fd7ba,
title = "A collaborative analysis of individual participant data from 19 prospective studies assesses circulating Vitamin D and prostate cancer risk",
abstract = "Previous prospective studies assessing the relationship between circulating concentrations of vitamin D and prostate cancer risk have shown inconclusive results, particularly for risk of aggressive disease. In this study, we examine the association between prediagnostic concentrations of 25-hydroxyvitamin D [25(OH)D] and 1,25-dihydroxyvitamin D [1,25(OH) 2 D] and the risk of prostate cancer overall and by tumor characteristics. Principal investigators of 19 prospective studies provided individual participant data on circulating 25(OH)D and 1,25(OH) 2 D for up to 13,462 men with incident prostate cancer and 20,261 control participants. ORs for prostate cancer by study-specific fifths of season-standardized vitamin D concentration were estimated using multivariable-adjusted conditional logistic regression. 25(OH)D concentration was positively associated with risk for total prostate cancer (mul-tivariable-adjusted OR comparing highest vs. lowest study-specific fifth was 1.22; 95{\%} confidence interval, 1.13–1.31; P trend < 0.001). However, this association varied by disease aggressiveness (P heterogeneity ¼ 0.014); higher circulating 25(OH)D was associated with a higher risk of nonaggressive disease (OR per 80 percentile increase ¼ 1.24, 1.13–1.36) but not with aggressive disease (defined as stage 4, metastases, or prostate cancer death, 0.95, 0.78–1.15). 1,25(OH) 2 D concentration was not associated with risk for prostate cancer overall or by tumor characteristics. The absence of an association of vitamin D with aggressive disease does not support the hypothesis that vitamin D deficiency increases prostate cancer risk. Rather, the association of high circulating 25(OH)D concentration with a higher risk of nonaggressive prostate cancer may be influenced by detection bias. Significance: This international collaboration comprises the largest prospective study on blood vitamin D and prostate cancer risk and shows no association with aggressive disease but some evidence of a higher risk of nonaggressive disease.",
keywords = "SERUM 25-HYDROXYVITAMIN D, D METABOLITES, SUBSEQUENT DEVELOPMENT, 1,25-DIHYDROXYVITAMIN-D, POLYMORPHISMS",
author = "{Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group} and Travis, {Ruth C.} and Aurora Perez-Cornago and Appleby, {Paul N.} and Demetrius Albanes and Joshu, {Corinne E.} and Lutsey, {Pamela L.} and Mondul, {Alison M.} and Platz, {Elizabeth A.} and Weinstein, {Stephanie J.} and Layne, {Tracy M.} and Helzlsouer, {Kathy J.} and Kala Visvanathan and Domenico Palli and Peeters, {Petra H.} and Bas Bueno-de-Mesquita and Antonia Trichopoulou and Gunter, {Marc J.} and Tsilidis, {Konstantinos K.} and Sanchez, {Maria Jose} and Anja Olsen and Hermann Brenner and Ben Schottker and Laura Perna and Bernd Holleczek and Paul Knekt and Harri Rissanen and Yeap, {Bu B.} and Leon Flicker and Almeida, {Osvaldo P.} and Wong, {Yuen Yee Elizabeth} and Chan, {June M.} and Giovannucci, {Edward L.} and Stampfer, {Meir J.} and Giske Ursin and Gislefoss, {Randi E.} and Tone Bj{\o}rge and Meyer, {Haakon E.} and Rune Blomhoff and Shoichiro Tsugane and Norie Sawada and English, {Dallas R.} and Eyles, {Darryl W.} and Heath, {Alicia K.} and Williamson, {Elizabeth J.} and Jonas Manjer and Johan Malm and Martin Almquist and {Le Marchand}, Loic and Haiman, {Christopher A.} and Wilkens, {Lynne R.} and Schenk, {Jeannette M.} and Tangen, {Cathy M.} and Amanda Black and Cook, {Michael B.} and Huang, {Wen Yi} and Ziegler, {Regina G.} and Martin, {Richard M.} and Hamdy, {Freddie C.} and Donovan, {Jenny L.} and Neal, {David E.} and Mathilde Touvier and Serge Hercberg and Pilar Galan and Melanie Deschasaux and Key, {Timothy J.} and Allen, {Naomi E.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1158/0008-5472.CAN-18-2318",
language = "English",
volume = "79",
pages = "274--285",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research (AACR)",
number = "1",

}

A collaborative analysis of individual participant data from 19 prospective studies assesses circulating Vitamin D and prostate cancer risk. / Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group.

In: Cancer Research, Vol. 79, No. 1, 01.01.2019, p. 274-285.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A collaborative analysis of individual participant data from 19 prospective studies assesses circulating Vitamin D and prostate cancer risk

AU - Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group

AU - Travis, Ruth C.

AU - Perez-Cornago, Aurora

AU - Appleby, Paul N.

AU - Albanes, Demetrius

AU - Joshu, Corinne E.

AU - Lutsey, Pamela L.

AU - Mondul, Alison M.

AU - Platz, Elizabeth A.

AU - Weinstein, Stephanie J.

AU - Layne, Tracy M.

AU - Helzlsouer, Kathy J.

AU - Visvanathan, Kala

AU - Palli, Domenico

AU - Peeters, Petra H.

AU - Bueno-de-Mesquita, Bas

AU - Trichopoulou, Antonia

AU - Gunter, Marc J.

AU - Tsilidis, Konstantinos K.

AU - Sanchez, Maria Jose

AU - Olsen, Anja

AU - Brenner, Hermann

AU - Schottker, Ben

AU - Perna, Laura

AU - Holleczek, Bernd

AU - Knekt, Paul

AU - Rissanen, Harri

AU - Yeap, Bu B.

AU - Flicker, Leon

AU - Almeida, Osvaldo P.

AU - Wong, Yuen Yee Elizabeth

AU - Chan, June M.

AU - Giovannucci, Edward L.

AU - Stampfer, Meir J.

AU - Ursin, Giske

AU - Gislefoss, Randi E.

AU - Bjørge, Tone

AU - Meyer, Haakon E.

AU - Blomhoff, Rune

AU - Tsugane, Shoichiro

AU - Sawada, Norie

AU - English, Dallas R.

AU - Eyles, Darryl W.

AU - Heath, Alicia K.

AU - Williamson, Elizabeth J.

AU - Manjer, Jonas

AU - Malm, Johan

AU - Almquist, Martin

AU - Le Marchand, Loic

AU - Haiman, Christopher A.

AU - Wilkens, Lynne R.

AU - Schenk, Jeannette M.

AU - Tangen, Cathy M.

AU - Black, Amanda

AU - Cook, Michael B.

AU - Huang, Wen Yi

AU - Ziegler, Regina G.

AU - Martin, Richard M.

AU - Hamdy, Freddie C.

AU - Donovan, Jenny L.

AU - Neal, David E.

AU - Touvier, Mathilde

AU - Hercberg, Serge

AU - Galan, Pilar

AU - Deschasaux, Melanie

AU - Key, Timothy J.

AU - Allen, Naomi E.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Previous prospective studies assessing the relationship between circulating concentrations of vitamin D and prostate cancer risk have shown inconclusive results, particularly for risk of aggressive disease. In this study, we examine the association between prediagnostic concentrations of 25-hydroxyvitamin D [25(OH)D] and 1,25-dihydroxyvitamin D [1,25(OH) 2 D] and the risk of prostate cancer overall and by tumor characteristics. Principal investigators of 19 prospective studies provided individual participant data on circulating 25(OH)D and 1,25(OH) 2 D for up to 13,462 men with incident prostate cancer and 20,261 control participants. ORs for prostate cancer by study-specific fifths of season-standardized vitamin D concentration were estimated using multivariable-adjusted conditional logistic regression. 25(OH)D concentration was positively associated with risk for total prostate cancer (mul-tivariable-adjusted OR comparing highest vs. lowest study-specific fifth was 1.22; 95% confidence interval, 1.13–1.31; P trend < 0.001). However, this association varied by disease aggressiveness (P heterogeneity ¼ 0.014); higher circulating 25(OH)D was associated with a higher risk of nonaggressive disease (OR per 80 percentile increase ¼ 1.24, 1.13–1.36) but not with aggressive disease (defined as stage 4, metastases, or prostate cancer death, 0.95, 0.78–1.15). 1,25(OH) 2 D concentration was not associated with risk for prostate cancer overall or by tumor characteristics. The absence of an association of vitamin D with aggressive disease does not support the hypothesis that vitamin D deficiency increases prostate cancer risk. Rather, the association of high circulating 25(OH)D concentration with a higher risk of nonaggressive prostate cancer may be influenced by detection bias. Significance: This international collaboration comprises the largest prospective study on blood vitamin D and prostate cancer risk and shows no association with aggressive disease but some evidence of a higher risk of nonaggressive disease.

AB - Previous prospective studies assessing the relationship between circulating concentrations of vitamin D and prostate cancer risk have shown inconclusive results, particularly for risk of aggressive disease. In this study, we examine the association between prediagnostic concentrations of 25-hydroxyvitamin D [25(OH)D] and 1,25-dihydroxyvitamin D [1,25(OH) 2 D] and the risk of prostate cancer overall and by tumor characteristics. Principal investigators of 19 prospective studies provided individual participant data on circulating 25(OH)D and 1,25(OH) 2 D for up to 13,462 men with incident prostate cancer and 20,261 control participants. ORs for prostate cancer by study-specific fifths of season-standardized vitamin D concentration were estimated using multivariable-adjusted conditional logistic regression. 25(OH)D concentration was positively associated with risk for total prostate cancer (mul-tivariable-adjusted OR comparing highest vs. lowest study-specific fifth was 1.22; 95% confidence interval, 1.13–1.31; P trend < 0.001). However, this association varied by disease aggressiveness (P heterogeneity ¼ 0.014); higher circulating 25(OH)D was associated with a higher risk of nonaggressive disease (OR per 80 percentile increase ¼ 1.24, 1.13–1.36) but not with aggressive disease (defined as stage 4, metastases, or prostate cancer death, 0.95, 0.78–1.15). 1,25(OH) 2 D concentration was not associated with risk for prostate cancer overall or by tumor characteristics. The absence of an association of vitamin D with aggressive disease does not support the hypothesis that vitamin D deficiency increases prostate cancer risk. Rather, the association of high circulating 25(OH)D concentration with a higher risk of nonaggressive prostate cancer may be influenced by detection bias. Significance: This international collaboration comprises the largest prospective study on blood vitamin D and prostate cancer risk and shows no association with aggressive disease but some evidence of a higher risk of nonaggressive disease.

KW - SERUM 25-HYDROXYVITAMIN D

KW - D METABOLITES

KW - SUBSEQUENT DEVELOPMENT

KW - 1,25-DIHYDROXYVITAMIN-D

KW - POLYMORPHISMS

UR - http://www.scopus.com/inward/record.url?scp=85059458026&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-18-2318

DO - 10.1158/0008-5472.CAN-18-2318

M3 - Article

VL - 79

SP - 274

EP - 285

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 1

ER -